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SR123781A: A New Once-Daily Synthetic
Oligosaccharide Anticoagulant for Thromboprophylaxis
After Total Hip Replacement Surgery
The DRIVE (Dose Ranging Study in Elective Total Hip Replacement
Surgery) Study
Michael R. Lassen, MD,* Ola Dahl, MD, PHD,† Patrick Mismetti, MD,‡ Dirk Zielske, MD,§
Alexander G. G. Turpie, MD, FACC
Hørsholm, Denmark; London, England; Saint-Étienne, France; Frankfurt am Main, Germany;
and Hamilton, Ontario, Canada
Objectives This study assessed the dose response of SR123781A for the prevention of venous thromboembolism (VTE) in
patients undergoing total hip replacement (THR) surgery.
Background Despite VTE preventive measures, residual VTE complications still occur after THR. SR123781A, a synthetic oligosac-
charide with a mixed profile of anti-factor Xa and IIa activities, could be an alternative to current treatments.
Methods In this double-blind study, 1,023 patients undergoing THR were randomly assigned to 1 of 5 daily doses of
SR123781A or to a calibrator arm of enoxaparin 40 mg. Treatment was continued for 10 days or until bilateral
venography was performed after a minimum of 5 days.
Results A significant dose-response effect for VTE was observed for SR123781A (p  0.0001). The VTE rates were
21.2%, 17.7%, 13.5%, 7.0%, and 4.4% in the 0.25-, 0.5-, 1.0-, 2.0-, and 4.0-mg dose groups of SR123781A,
respectively, and 8.7% in the enoxaparin group. Doses of 2.0 and 4.0 mg of SR123781A reduced the risk of
VTE by 67% and 79%, respectively, compared with the 0.25-mg dose group. Major bleeding was observed in
1.2%, 0.6%, 0.6%, 0.6%, and 5.8% of the patients in the 0.25-, 0.5-, 1.0-, 2.0-, and 4.0-mg dose groups of
SR123781A, respectively, and in 0.6% of patients in the enoxaparin group. The dose-response effect for
major bleeding was significant (p  0.0037).
Conclusions The model based on these dose-finding study results suggests that SR123781A doses ranging from 1.5 to 2.5
mg show a reasonable risk-to-benefit ratio for VTE prevention after major orthopedic surgery. (Dose Ranging
Study in Elective Total Hip Replacement Surgery [DRIVE]; NCT00338897) (J Am Coll Cardiol 2008;51:
1498–504) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.007v
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Pith an aging population, the number of people under-
oing total hip replacement (THR) surgery is expected to
ncrease over the coming decades. In the U.S., the annual
umber of primary THRs is expected to increase by 174%
etween 2005 and 2030, and the number of total hip
evisions is projected to grow by 137% over this time
eriod (1).
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aPatients undergoing THR surgery are at high risk of
enous thromboembolism (VTE). Historically, approxi-
ately 40% to 60% of such patients develop deep vein
hrombosis (DVT) in the absence of prophylaxis (2,3) and
.2% develop fatal pulmonary embolism (PE) (4–6). Cur-
ent guidelines from the American College of Chest Phy-
icians recommend that all patients undergoing THR sur-
conomic compensation from sanofi-aventis for the work done in the scientific
teering Committee; Dr. Mismetti has served as a member of Steering Committees
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April 15, 2008:1498–504 Prevention of VTE With SR123781Aery receive thromboprophylaxis with a low-molecular-
eight heparin, vitamin K antagonist, or fondaparinux (2).
lthough heparins and vitamin K antagonists are widely
sed to prevent VTE in this setting, residual VTE compli-
ations can still occur.
Recently, specific factor Xa inhibitors such as fondapa-
inux, and anticoagulants with pure anti-factor IIa proper-
ies, such as dabigatran, have been developed (7,8).
R123781A is the first synthetic oligosaccharide developed
hat has a mixed profile of antithrombin-dependent anti-
actor Xa and IIa activities. This synthetic hexadecasaccha-
ide has been shown to have marked antithrombotic activity
n animal models of arterial and venous thrombosis (9–11).
uman studies have shown that SR123781A administered
ubcutaneously is completely absorbed, reaching a maxi-
um concentration 4 h post-dosing, and that SR123781A
as a half-life of 11 to 16 h (data on file). SR123781A
hows dose-proportional and linear pharmacokinetics over
he dose range studied (0.8 to 18 mg) (data on file).
The objective of this study was to assess the dose response
f SR123781A for the prevention of VTE in patients
ndergoing THR surgery.
ethods
tudy design. This was a multicenter, multinational, ran-
omized, double-blind, double-dummy, dose-ranging study
f SR123781A (sanofi-aventis, Paris, France) for the pre-
ention of VTE in patients undergoing elective THR
urgery, with an enoxaparin (Clexane/Lovenox; sanofi-
ventis) calibrator arm. The calibrator arm was used to
nsure that the study design reflects a representative stan-
ard; enoxaparin was not intended for use in statistical
omparisons. The study was conducted in accordance with
he International Conference on Harmonisation Guidelines
or Good Clinical Practice and the Declaration of Helsinki.
he research protocol was approved by an institutional
eview board at each participating center.
After obtaining written informed consent, patients were
andomized to receive SR123781A at doses 0.25, 0.5, 1.0,
.0, and 4.0 mg, or enoxaparin 40 mg. SR123781A (single-
se vials) was administered subcutaneously 8  1 h after
urgery and once-daily thereafter in the morning (every 24
2 h). Enoxaparin (0.4 ml pre-filled syringes) was initiated
ither 12  1 h before surgery or post-operatively (in the
ase of loco-regional anesthesia) according to local labeling
nd the usual practice of the participating center. Subcuta-
eous treatment with enoxaparin was continued once daily.
oth treatments were administered for a minimum of 5 days
nd a maximum of 10 days after surgery. Mandatory
ilateral venography was performed no later than 1 day after
he administration of the last dose of study medication, and
fter a minimum of 5 days of study drug administration.
he use of nonsteroidal anti-inflammatory drugs was dis-ouraged, and intermittent pneumatic compression was not termitted during the treatment
eriod. Prolonged thrombopro-
hylaxis was recommended and
as at the discretion of the in-
estigator. Patients attended a
linical follow-up visit 30  3
ays after surgery.
atients. Patients were enrolled
nto the study if they were age
18 years and were undergoing
lective THR surgery or a revision
f at least 1 component of a THR
hat had been performed at least 6 months before entry into the
tudy.
Exclusion criteria included major orthopedic surgery
ithin the previous 3 months before the study; clinical signs
r symptoms of VTE in the previous 12 months; myocardial
nfarction or stroke in the previous 3 months; past or present
leeding disorder; uncontrolled hypertension; contraindica-
ion to heparin therapy or sensitivity to iodinated contrast
edium; treatment with anticoagulant or antiplatelet drugs
n the week before surgery; recent trauma, major surgery,
ye surgery, or parenchymal organ biopsy; a current addic-
ive disorder; serum creatinine level 2 mg/dl; thrombocy-
openia; significant anemia; history of hemorrhagic stroke;
tructural damage to the central nervous system; and pro-
ressive malignant disease. Women were excluded if they
ere pregnant or nursing or were not using effective
ontraception.
hromboembolic events. The primary efficacy end point
as a composite of the following VTE events: any DVT
dentified on mandatory venography of the lower limbs,
ymptomatic DVT and/or nonfatal PE, and VTE-related
eath (fatal PE and unexplained death). The VTE events
ere evaluated 5 to 11 days after surgery, or earlier if the
atient developed symptoms of VTE. Secondary efficacy
nd points included any DVT, proximal and isolated distal
VT, fatal and nonfatal PE, and any confirmed symptom-
tic VTE.
Patients were screened for DVT with bilateral venography 5
o 11 days after surgery, or sooner if signs and symptoms were
resent. Venography was performed according to the tech-
ique of Rabinov and Paulin (12). The PE was confirmed by
perfusion/ventilation lung scan and/or pulmonary angiogra-
hy or spiral computerized tomography. All VTE events were
onfirmed by an independent and blinded adjudication com-
ittee (Hamilton, Ontario, Canada).
afety. The primary safety criterion was the incidence of
ajor bleeding, adjudicated by an independent committee,
etween the first dose of study drug and 3 days after the last
njection. Major bleeding included fatal bleeding, surgical
ite bleeding leading to intervention, bleeding that was
etroperitoneal or intracranial or that involved any other
ritical organ (eye, adrenal gland, pericardium, or spine),
nd non–surgical site bleeding requiring surgical interven-
Abbreviations
and Acronyms
CI  confidence interval
DVT  deep vein
thrombosis
PE  pulmonary embolism
THR  total hip
replacement
VTE  venous
thromboembolismion or non–surgical site overt bleeding with a bleeding
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Prevention of VTE With SR123781A April 15, 2008:1498–504ndex of 2. The bleeding index was calculated as the
ifference between pre-bleeding and post-bleeding hemo-
lobin plus the number of transfused blood units. Minor
leeding was defined as clinically overt bleeding that did not
eet the criteria for major bleeding. Adverse events were
lso monitored during the study. The safety population was
omposed of all randomized patients who received at least 1
ose of study drug and underwent THR surgery. An
ndependent Data Monitoring Committee continuously
onitored safety and efficacy in this study; the committee
id not recommend any changes to the protocol.
tatistical analysis. All statistical analyses were carried out
sing SAS version 8.2 (SAS Institute Inc., Cary, North
arolina). Assuming event rates for the primary efficacy end
oint of 5% to 15%, and also that 30% of randomized
atients would not be evaluable for the primary efficacy
nalysis, 170 patients were calculated to be required in each
f the dose groups to provide 80% power to detect a dose
ffect for the 5 doses of SR123781A.
The primary efficacy analysis—to show a dose-response
elationship for SR123781A in the prevention of VTE—
as performed on the group of patients who received at least
dose of study drug, who underwent THR surgery, and
ho had an evaluable efficacy end point. The incidence of
he primary end point was compared across the SR123781A
ose groups using a 2-sided Cochran-Armitage test trend at
Figure 1 DRIVE Study Patients Flow Diagram
DRIVE  Dose Ranging Study in Elective Total Hip Replacement Surgery.
easons for Prematurely Discontinuing Study Drug in the Safety Po
Table 1 Reasons for Prematurely Discontinuing Study Drug in t
Reason, n (%)
S
0.25 mg
(n  171)
0.5 mg
(n  163)
Adverse event 2 (1.2) 0 (0)
Patient’s request 1 (0.6) 0 (0)
Other 0 (0) 0 (0)Any reason 3 (1.8) 0 (0) 2 (1he 0.05 significance level, using the values of the logarithm
f the doses as score and a logistic regression model
ncluding logarithmic dose levels as covariates. Also, pair-
ise comparisons were made between the 4.0- and 0.25-mg
ose of SR123781A using the 2-sided Fisher exact test at
he 0.05 significance level. Comparisons of the next highest
ose level to the 0.25 mg dose were performed if the p value
or the previous comparison was 0.05. Safety end points
ere analyzed on the safety population.
esults
tudy population. A total of 1,080 patients were enrolled
etween June 1, 2006, and April 3, 2007, at 53 centers in 12
ountries, and a total of 1,023 were randomized to receive
ither SR123781A or enoxaparin (Fig. 1). The main reasons
or not being randomized to study treatment were lack of
ligibility (n  11) and at the patient’s request (n  23).
ourteen patients who were randomized did not receive any
tudy drug, 11 in the SR123781A dose groups and 3 in the
noxaparin group, because of adverse events (n  7),
atients’ request (n  4), or other reasons (n  3). Of the
emaining 1,009 patients who compose the safety popula-
ion, 843 received SR123781A and 166 received enoxapa-
in. Twenty-six patients from the safety population prema-
urely stopped the study drug, mostly (20 patients) because
tion
fety Population
781A
Enoxaparin
40 mg
(n  166)
g
70)
2.0 mg
(n  168)
4.0 mg
(n  171)
.2) 1 (0.6) 12 (7.0) 3 (1.8)
) 0 (0) 1 (0.6) 0 (0)
) 0 (0) 3 (1.8) 1 (0.6)pula
he Sa
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April 15, 2008:1498–504 Prevention of VTE With SR123781Af an adverse event (Table 1). The primary efficacy popu-
ation comprised 736 patients; 610 received SR123781A
nd 126 received enoxaparin. Six patients from the primary
fficacy population prematurely stopped the study drug
reatment, mostly (5 patients) because of a serious adverse
vent.
The 6 treatment groups were similar with respect to
emographic variables, surgical characteristics, or VTE risk
actor profiles (Table 2).
Approximately 35% of the patients received a pre-
perative injection of study drug. The median duration of
reatment was similar across all treatment groups (9 days for
hose in the 0.25-, 0.5-, 1.0-, and 2.0-mg SR123781A dose
roups and the enoxaparin group and 8 days for those in the
.0-mg SR123781A dose group).
fficacy outcomes. The incidence of confirmed VTE in
atients in the primary efficacy population is shown in Table
. The rates of confirmed VTE were 21.2%, 17.7%, 13.5%,
.0%, and 4.4% in the 0.25-, 0.5-, 1.0-, 2.0-, and 4.0-mg
R123781A dose groups, respectively. The incidence of
TE in the enoxaparin calibrator arm was 8.7%. A clear
ose-response effect was observed for SR123781A (p 
aseline Characteristics, Surgery Details, and Venous Thromboembisk Factor Profil s of Patients in the Safety Population (N  1,00
Table 2 Baseline Characteristics, Surgery Details, and VenousRisk Factor Profiles of Patients in the Safety Populatio
Characteristic, n (%)
0.25 mg
(n  171)
0.5 mg
(n  163)
Median age (range), yrs 59 (25–86) 60 (18–86)
Female 100 (58.5) 96 (58.9)
Caucasian 156 (91.2) 151 (92.6)
Median weight (range), kg 78 (50–128) 75 (43–116)
Body mass index 30 kg/m2 57 (33.5) 36 (22.1)
History of thromboembolism 0 (0) 2 (1.2)
History of cancer 5 (2.9) 5 (3.1)
Surgery details
Primary surgery 168 (98.2) 158 (96.9)
Cemented prosthesis 68 (39.8) 64 (39.3)
Mean duration of surgery  SD, min 92 44 87 34
Type of anesthesia
General only 34 (19.9) 28 (17.2)
Regional only 133 (77.8) 133 (81.6)
ncidence and Risk of Confirmed Venous Thromboembolism (VTE) a
Table 3 Incidence and Risk of Confirmed Venous Thromboembo
Parameter 0.25 mg 0.5 mg
Confirmed VTE, n/N 25/118 22/124
Percent (95% CI) 21.2 (14.2–29.7) 17.7 (11.5–25.6) 1
p value* — —
Relative risk (95% CI)* — 0.84 (0.50–1.40) 0
Proximal DVT, n/N 9/135 9/143
Percent (95% CI) 6.7 (3.1–12.3) 6.3 (2.9–11.6)
p value* — 1.00
Relative risk (95% CI)* — 0.94 (0.39–2.26) 0For comparison with 0.25 mg SR123781A.
CI  confidence interval; DVT  deep vein thrombosis; VTE  venous thromboembolism..0001). Using a logarithmic model, the incidence of
atients with VTE was shown to decrease with increasing
oses of SR123781A (p  0.0001) (Fig. 2). The
R123781A 2.0- and 4.0-mg doses were significantly more
ffective at preventing VTE compared with the 0.25-mg
ose, reducing the risk of VTE by 67% (95% confidence
nterval [CI] 33% to 84%) and 79% (95% CI 50% to 92%),
espectively (Table 3).
No events of symptomatic VTE were confirmed during
he study. Statistical analysis showed a significant dose-
esponse relationship between SR123781A and proximal
VT (p  0.0001). The 1.0-, 2.0-, and 4.0-mg doses of
R123781A were significantly more effective at preventing
roximal DVT compared with the 0.25-mg dose. There
ere no events of proximal DVT in the 4.0-mg SR123781A
ose group, and the risk of proximal DVT was reduced by
0% and 90% in the 1.0- and 2.0-mg dose groups of
R123781A, respectively (Table 3).
afety outcomes. The frequency of major bleeding and all
leeding in the different treatment groups is presented in
able 4. Major bleeding was observed in 1.2%, 0.6%, 0.6%,
.6%, and 5.8% of the patients in the 0.25-, 0.5-, 1.0-, 2.0-,
boembolism
 1,009)
SR123781A
Enoxaparin
40 mg
(n  166)
1.0 mg
(n  170)
2.0 mg
(n  168)
4.0 mg
(n  171)
60 (33–83) 60 (25–90) 58 (23–86) 59 (28–83)
100 (58.8) 98 (58.3) 99 (57.9) 102 (61.4)
157 (92.4) 153 (91.1) 156 (91.2) 153 (92.2)
76 (46–128) 76 (47–129) 78 (42–133) 75 (45–122)
58 (34.3) 45 (26.8) 50 (29.2) 48 (28.9)
1 (0.6) 0 (0) 2 (1.2) 1 (0.6)
3 (1.8) 4 (2.4) 3 (1.8) 8 (4.8)
161 (94.7) 159 (95.2) 165 (96.5) 160 (96.4)
72 (42.4) 61 (36.5) 63 (36.8) 62 (37.3)
89 36 91 39 95 44 89 36
27 (15.9) 23 (13.8) 27 (15.8) 26 (15.7)
140 (82.4) 140 (83.8) 139 (81.3) 137 (82.5)
roximal Deep Vein Thrombosis (DVT)
(VTE) and Proximal Deep Vein Thrombosis (DVT)
3781A
Enoxaparin
40 mg0 mg 2.0 mg 4.0 mg
/126 9/128 5/114 11/126
.1–20.7) 7.0 (3.3–12.9) 4.4 (1.4–9.9) 8.7 (4.4–15.1)
.13 0.0015 0.0001 —
.36–1.11) 0.33 (0.16–0.67) 0.21 (0.08–0.50) —
/147 1/149 0/130 2/136
.2–4.8) 0.7 (0.0–3.7) 0.0 (0.0–2.8) 1.5 (0.2–5.2)
.029 0.0077 0.0034 —
.03–0.85) 0.10 (0.01–0.61) 0.00 (0.00–0.44) —olism9)
Throm
n (Nnd P
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Prevention of VTE With SR123781A April 15, 2008:1498–504nd 4.0-mg SR123781A dose groups, respectively. There
as a significant dose-response effect for major bleeding (p
0.0037) and any bleeding (p  0.0001) in the safety
opulation. The incidence of major bleeding in the enox-
parin calibrator arm was 0.6%. Using a logarithmic model,
he incidence of patients with major bleeding was shown to
ncrease with increasing doses of SR123781A (p  0.0067)
Fig. 2). The 4.0-mg dose of SR123781A was associated
ith a significantly higher rate of major bleeding and any
leeding compared with the 0.25-mg dose (Table 4). There
as a 5-fold increase in the risk of major bleeding (relative
isk 5.00; 95% CI 1.25 to 27.0) and 6-fold increase in the
isk of any bleeding (relative risk 6.00; 95% CI 2.85 to 12.7)
n the 4.0-mg dose group, compared with the lowest dose
roup (0.25 mg).
5
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Figure 2 Dose-Response Curves for SR123781A
Incidence of confirmed adjudicated venous thromboembolism (VTE) (blue) from
surgery up to 10 days post-surgery or day of mandatory venography (whichever
came first), and incidence of confirmed adjudicated major bleeding (red) from
first study drug injection up to last study drug injection plus 3 days. Point esti-
mates for SR123781A groups (dots) and enoxaparin group (circles), and logis-
tic regression curve (solid lines) with 2-sided 95% confidence intervals (dotted
lines).
ncidence of Bleeding End Points
Table 4 Incidence of Bleeding End Points
Bleeding Classification
0.25 mg
(n  171)
Major bleeding, n 2
Percent (95% CI) 1.2 (0.1–4.2) 0.
Fatal bleeding, n (%) 1 (0.6)
Surgical site bleeding leading to intervention, n (%) 1 (0.6)
Non–surgical site bleeding with bleeding index 2, n (%) 0 (0)
Any bleeding, n 7
Percent (95% CI) 4.1 (1.7–8.3) 5.p  0.035 versus 0.25-mg SR123781A; †p  0.0001 versus 0.25-mg SR123781A.
CI  confidence interval.No bleeding into a critical organ was reported, and no
atient developed a stroke or a myocardial infarction.
pproximately one-half of the major bleeding events were
onfined to the surgical site (Table 4).
Two patients died during the study: 1 patient in the
.25-mg SR123781A dose group died 1 day post-surgery of
hypovolemia leading to a myocardial infarction and death
confirmed by the adjudication committee as fatal bleeding),
nd 1 patient in the 4.0-mg SR123781A dose group died of
n encephalopathic brain hypoxia (confirmed by the adju-
ication committee to be unrelated to bleeding or VTE)
ccurring 44 days post-surgery.
No dose arm was stopped prematurely because of safety
oncerns. The proportion of patients experiencing adverse
vents in the 4.0-mg dose group (60.2%) was nearly double
hat in the other groups (33.9%, 41.7%, 31.8%, and 32.7%
n the 0.25-, 0.5-, 1.0-, and 2.0-mg SR123781A dose
roups respectively, and 36.1% in the enoxaparin group).
imilarly, more patients in the 4.0-mg dose group experi-
nced drug-related or serious adverse events during treat-
ent (most of those were bleeding events).
iscussion
he results of this study show a statistically significant
ose-response effect for SR123781A for both efficacy and
afety outcomes. Therefore, the main objective of the study
as accomplished. The incidence of VTE after THR
urgery decreased with increasing doses of SR123781A, and
he highest dose of SR123781A tested was associated with
n increased rate of major bleeding compared with the
owest dose (0.25 mg).
The doses of SR123781A investigated in this study were
ased on previous experience with the compound (9,13)
data on file). Enoxaparin was chosen as the calibrator arm
n the current study because low-molecular-weight heparins
re currently recommended by the American College of
hest Physicians for the prevention of VTE after THR
urgery (2) and of the low-molecular-weight heparins,
noxaparin is the most commonly used around the world. A
nce-daily regimen of 40 mg enoxaparin was chosen in
SR123781A
Enoxaparin
40 mg
(n  166)
g
63)
1.0 mg
(n  170)
2.0 mg
(n  168)
4.0 mg
(n  171)
1 1 10* 1
3.4) 0.6 (0.0–3.2) 0.6 (0.0–3.3) 5.8 (2.8–10.5) 0.6 (0.0–3.3)
0 (0) 0 (0) 0 (0) 0 (0)
1 (0.6) 0 (0) 5 (2.9) 0 (0)
0 (0) 1 (0.6) 5 (2.9) 1 (0.6)
5 11 42† 6
10.2) 2.9 (1.0–6.7) 6.5 (3.3–11.4) 24.6 (18.3–31.7) 3.6 (1.3–7.7)0.5 m
(n  1
1
6 (0.0–
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ountries.
Recently conducted dose-ranging studies of specific fac-
or Xa or IIa inhibitors have consistently shown a dose-
esponse relationship for major bleeding, although not all
ave shown a dose response for efficacy (14–17). A study of
ndirect factor Xa inhibition with the synthetic pentasac-
haride fondaparinux 0.75 to 8.0 mg/day showed a dose-
esponse relationship for this anticoagulant for VTE pre-
ention and major bleeding in patients undergoing THR
urgery (14). Major bleeding rates of 17% were observed,
ith the 2 highest doses (6.0 and 8.0 mg) necessitating
remature discontinuation of these doses from the study.
ose-ranging studies of the direct factor Xa inhibitor,
ivaroxaban, either once daily or twice daily (5 to 80 mg),
id not show a dose response for efficacy, but did reveal a
ose response for major bleeding in patients undergoing
HR surgery (15,16). Direct inhibition of thrombin with
abigatran has also been evaluated in patients undergoing
ajor orthopedic surgery. A dose-response relationship was
hown over a dose range from 100 to 450 mg/day for both
fficacy and safety outcomes (17).
The current study was not designed to compare the
fficacy of SR123781A to that of enoxaparin. Enoxaparin
as included as a calibrator arm and was associated with
imilar rates of VTE, although lower rates of major bleed-
ng, compared with other studies that used a similar patient
opulation, treatment duration, and primary end points
14,18,19). The results of this study suggest that a similar
roportion of patients receiving 2.0 mg SR123781A or 40
g enoxaparin experienced confirmed events of VTE (7.0%
nd 8.7%, respectively). In addition, a similar proportion of
atients receiving 0.5, 1.0, and 2.0 mg SR123781A or 40
g enoxaparin experienced major bleeding (0.6% for each
f these groups).
tudy limitations. A potential limitation of our study is
hat only 72% of randomized patients were eligible for the
rimary efficacy analysis. However, this eligibility rate is
imilar to that seen in contemporary clinical studies of
nticoagulants in patients undergoing major orthopedic
urgery. For example, 71% to 76% of patients were eligible
or the primary efficacy analysis in similar dose-ranging
tudies of rivaroxaban for VTE prevention after THR
urgery (15,16), 64% were eligible in a similar study of
ondaparinux (14), and 75% were eligible in a dose-ranging
tudy of dabigatran in patients undergoing major orthopedic
urgery (17).
onclusions
n summary, there was a dose-related increase in VTE
revention with SR123781A over a 16-fold dose range in
atients at high risk of developing thrombosis in the present
tudy. The highest dose of SR123781A was associated with
1n increased rate of major bleeding. Based on the data
btained in this dose-ranging study, the resulting model
uggests that SR123781A doses ranging from 1.5 to 2.5 mg
how a reasonable risk-to-benefit ratio for the prevention of
TE in patients undergoing major orthopedic surgery.
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